CRNX Crinetics Pharmaceuticals, Inc.

CIK 0001658247 41 ready 8-Ks latest May 7, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: auditor change (2)

Ready 8-Ks 41

Latest filing May 7, 2026, 7:59 PM ET

Top materiality 0.90

Event mix other_material ×17 · earnings ×11 · leadership ×8

Sentiment 14 pos · 2 neg · 25 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for CRNX

Highest-materiality recent filing

Crinetics gets FDA approval for PALSONIFY (paltusotine) as first oral acromegaly treatment

September 26, 2025, 7:59 PM ET regulatory materiality 0.90 positive item 7.01 item 8.01 item 9.01

FDA approved PALSONIFY (paltusotine) for adults with acromegaly with inadequate response to surgery or not surgical candidates.
First once-daily oral SST2 agonist; approval based on Phase 3 PATHFNDR-1/2 trials showing rapid, durable biochemical control and reduced symptom burden.

Read filing →

May 7, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Crinetics Q1 2026: PALSONIFY net revenue $10.3M; EU approval; net loss $127.8M

PALSONIFY net product revenue $10.3M in Q1 2026, up from $5.4M in Q4 2025; 232 enrollment forms received.
March 23, 2026, 7:59 PM ET leadership materiality 0.60 negative item 5.02

Crinetics' Chief Development and Operating Officer resigns effective April 10, 2026

Jeff Knight resigns as Chief Development and Operating Officer, effective April 10, 2026.
February 26, 2026, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Crinetics Q4 2025: Palsonify launch revenue $5.4M, net loss $122.8M; EU CHMP positive opinion

PALSONIFY net product revenue $5.4M in Q4 2025; >200 enrollment forms by Dec end; 125+ HCPs prescribed in Q4.
January 13, 2026, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 7.01 item 9.01

Crinetics reiterates preliminary Q4 2025 PALSONIFY net product revenue over $5.0M

Net product revenue from PALSONIFY (paltusotine) exceeds $5.0M for Q4 2025.
January 7, 2026, 6:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

Crinetics prices $350M common stock offering at $45.95/share to fund PALSONIFY launch

Pricing: 7,620,000 shares at $45.95/share; gross proceeds ~$350M.
January 5, 2026, 6:59 PM ET other material materiality 0.85 positive item 2.02 item 7.01 item 8.01 item 9.01

Crinetics PALSONIFY Q4 net revenue >$5M; atumelnant Phase 2 CAH shows 67% A4 reduction

Unaudited Q4 2025 PALSONIFY net product revenue exceeded $5.0M, with >200 enrollment forms and >125 unique prescribers.
December 17, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

Crinetics CMO Dana Pizzuti steps down; transitions to advisor roles with $577k severance

Dr. Dana Pizzuti steps down as CMO effective Dec 31, 2025; serves as Strategic Regulatory and Development Advisor through Mar 31, 2026.
November 6, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Crinetics Q3 net loss $130.1M; PALSONIFY launched for acromegaly after FDA approval

PALSONIFY (paltusotine) approved by FDA Sept 25 for first-line acromegaly; ~95% of top-priority HCP targets called, ~50% of filled prescriptions reimbursed.
September 26, 2025, 7:59 PM ET regulatory materiality 0.90 positive item 7.01 item 8.01 item 9.01

Crinetics gets FDA approval for PALSONIFY (paltusotine) as first oral acromegaly treatment

FDA approved PALSONIFY (paltusotine) for adults with acromegaly with inadequate response to surgery or not surgical candidates.
August 7, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Crinetics reports Q2 net loss $115.6M; PDUFA for paltusotine on Sept 25, 2025

Revenue $1.0M (vs $0.4M in Q2 2024); net loss widened to $115.6M from $74.1M YoY.
June 26, 2025, 7:59 PM ET other material materiality 0.60 neutral item 7.01 item 8.01 item 9.01

Crinetics R&D Day updates preclinical pipeline: TSHR antagonist, SST3 agonist, NDC platform

CRN12755 (TSHR antagonist) decreased thyroid hormone (T4) in rat model and hyaluronic acid/IL-6 in TED patient orbital fibroblasts.
February 27, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Crinetics reports FY2024 net loss $298.4M; cash $1.4B; paltusotine PDUFA Sept 25, 2025

Net loss Q4 2024: $80.6M vs $60.1M YoY; full year $298.4M vs $214.5M.
February 24, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Crinetics appoints Tobin Schilke as CFO effective Feb 28, 2025

Tobin Schilke appointed CFO effective February 28, 2025, succeeding Marc Wilson.
January 14, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Crinetics outlines 2025 milestones: paltusotine PDUFA Sept 25, atumelnant Ph3 start H1 2025

Paltusotine NDA under FDA review; PDUFA target action date set for September 25, 2025.
January 10, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Crinetics' atumelnant Phase 2 CAH trial meets primary endpoint with up to 80% mean A4 reduction

Atumelnant reduced androstenedione up to 80% (120mg, p<0.0001); 80mg dose reduced by 774 ng/dL (p<0.0001).
December 16, 2024, 6:59 PM ET leadership materiality 0.65 positive item 5.02 item 7.01 item 9.01

Crinetics appoints Isabel Kalofonos as CCO ahead of paltusotine launch

Isabel Kalofonos named Chief Commercial Officer, effective Dec 16, 2024; leads paltusotine (once-daily SST2 agonist for acromegaly) launch prep and pipeline commercialization.
December 9, 2024, 6:59 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

Crinetics announces FDA acceptance of NDA for paltusotine in acromegaly; PDUFA Sept 25, 2025

FDA accepted Crinetics' NDA for once-daily oral paltusotine for adult acromegaly patients.
November 12, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Crinetics reports Q3 net loss $76.8M; submits NDA for paltusotine; raises $575M

Net loss of $76.8M in Q3 2024 vs $57.5M in Q3 2023; revenue $0 vs $0.3M from SKK licensing.
October 9, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

Crinetics prices upsized $500M public offering at $50/share; net proceeds ~$472M

Pricing of 10,000,000 shares of common stock at $50.00/share for gross proceeds of $500.0 million.
September 26, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Crinetics submits NDA to FDA for paltusotine for acromegaly; Phase 3 data support submission

NDA supported by 18 clinical trials including two Phase 3 PATHFNDR studies; all primary and secondary endpoints met.
September 17, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

Crinetics CCO James Hassard to depart effective October 14, 2024

James Hassard separates as Chief Commercial Officer; last day October 14, 2024.
August 8, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 5.02 item 9.01 ◈ executive_change

Crinetics Q2 net loss $74.1M; CFO Wilson departs; paltusotine NDA on track for H2 2024

Net loss of $74.1M in Q2 2024 vs $51.0M in Q2 2023; R&D expenses rose to $58.3M from $40.6M.
June 21, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

Crinetics enters ATM equity offering agreement for up to $350M

Filed prospectus supplement registering up to $350M in common stock sales.
June 3, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Crinetics posts positive Phase 2 data for atumelnant; paltusotine NDA on track for 2H 2024

Atumelnant: 100% of CAH (n=6) achieved A4 below ULN; 100% of ADCS (n=5) normalized UFC at 80 mg once daily.
May 9, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Crinetics Q1 net loss $66.9M; paltusotine NDA on track for 2H 2024

Net loss of $66.9M in Q1 2024 vs $46.0M in Q1 2023; revenue fell to $0.6M from $2.7M.
May 8, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Crinetics to present initial atumelnant Phase 2 data in CAH and Cushing's at ENDO 2024

Five abstracts, four late-breaking, to be presented at ENDO 2024 (June 1-4, Boston).
March 19, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Crinetics paltusotine meets all endpoints in Phase 3 acromegaly study; NDA planned 2H 2024

Primary endpoint: 56% of paltusotine patients achieved IGF-1 ≤1.0 xULN vs 5% placebo (p<0.0001).
March 12, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Crinetics reports positive Phase 2 results for paltusotine in carcinoid syndrome

Phase 2 trial: 63% reduction in mean flushing frequency (p<0.0001) for patients with >1/day at baseline.
March 1, 2024, 6:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements

Crinetics raises $350M in oversubscribed private placement of 8.33M shares at $42/sh

Private placement of 8,333,334 common shares at $42.00/share raises ~$350M gross proceeds.
February 28, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Crinetics reports Q4 net loss of $60.1M; announces $350M private placement; paltusotine NDA on track for 2H 2024

Net loss for Q4 2023 was $60.1M vs $45.0M in Q4 2022; full-year net loss $214.5M vs $163.9M in 2022.